BIO5 member Emmanuel Katsanis of the University of Arizona Comprehensive Cancer Center has transformed pediatric cancer care in Arizona, leading advances in bone marrow transplantation and immunotherapy that have raised survival rates and expanded access to lifesaving treatments.

BIO5 member John Elfar led a UArizona study showing the multiple sclerosis drug 4-aminopyridine accelerates bone fracture healing in mice. The drug boosted BMP2 activity, bone mass, and osteoblast growth, suggesting potential for faster, stronger recovery in future clinical applications.

BIO5 member Andrea Achilli leads the University of Arizona’s role in a $38M U.S. Army ERDC Water Reuse Consortium, advancing smart treatment systems, sustainable brine management, and virus detection.

BIO5 member Goggy Davidowitz co-founded Kuairu to commercialize a solar-powered drying tower that reduces food waste by rapidly preserving surplus produce while lowering emissions and promoting sustainable agriculture.

BIO5 member Fiona Bailey of the University of Arizona has developed a smartphone app and device that use resistive breath training to lower blood pressure, offering a time-efficient alternative to medication and traditional exercise for managing hypertension

What began as an internship at the University of Arizona BIO5 Institute grew into a path of mentorship, leadership, and discovery for Drew Seiser.

BIO5 member Jianqin Lu and colleagues developed a new paclitaxel formulation, Paclitaxome, that improves drug delivery to tumors while reducing side effects.

BIO5 member Maya Kaelberer co-led a study uncovering a “gut sense” where colon neuropod cells directly signal the brain when bacteria release flagellin during eating.

BIO5 member Sairam Parthasarathy leads research at the UArizona Center for Sleep, Circadian and Neuroscience Research, advancing sleep medicine through studies on sleep apnea, circadian health, COVID-19, and Alzheimer’s while promoting equity and technology in health care.

BIO5 member Stefano Guerra is leading a $3.8M NIH-funded study to test whether low levels of the lung protein CC16 in childhood can predict early COPD risk in adulthood.